Beacon Financial Group Sells 1,036 Shares of Johnson & Johnson (NYSE:JNJ)

Beacon Financial Group trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,615 shares of the company’s stock after selling 1,036 shares during the period. Beacon Financial Group’s holdings in Johnson & Johnson were worth $2,981,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of JNJ. Signet Investment Advisory Group Inc. raised its holdings in shares of Johnson & Johnson by 1.9% during the 4th quarter. Signet Investment Advisory Group Inc. now owns 26,689 shares of the company’s stock worth $3,860,000 after buying an additional 497 shares in the last quarter. TCV Trust & Wealth Management Inc. raised its stake in Johnson & Johnson by 1.9% during the fourth quarter. TCV Trust & Wealth Management Inc. now owns 98,726 shares of the company’s stock worth $14,278,000 after acquiring an additional 1,820 shares in the last quarter. David Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $316,000. Portfolio Design Labs LLC grew its holdings in shares of Johnson & Johnson by 35.2% during the 4th quarter. Portfolio Design Labs LLC now owns 18,318 shares of the company’s stock valued at $2,649,000 after purchasing an additional 4,774 shares during the last quarter. Finally, Augustine Asset Management Inc. increased its position in Johnson & Johnson by 13.9% during the 4th quarter. Augustine Asset Management Inc. now owns 3,505 shares of the company’s stock worth $507,000 after purchasing an additional 427 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 0.7 %

Shares of Johnson & Johnson stock opened at $156.20 on Friday. The stock’s 50-day moving average is $147.73 and its 200 day moving average is $156.01. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The firm has a market cap of $376.08 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Stifel Nicolaus decreased their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Bank of America lowered their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Guggenheim upped their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Finally, Leerink Partners reduced their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.